ADA/EASD Position Statement: Approach to Hyperglycemia Management

Slides:



Advertisements
Similar presentations
Guidelines.diabetes.ca | BANTING ( ) | diabetes.ca Copyright © 2013 Canadian Diabetes Association CHOICE OF AGENT AFTER INITIAL METFORMIN.
Advertisements

Clinical Outcomes with Newer Antihyperglycemic Agents
Case-Based Examination of Treatment Options in Type 2 Diabetes Management.
Clinical Outcomes with Newer Antihyperglycemic Agents
Cardiovascular Challenges in Diabetes
EMPA-REG OUTCOME: The Endocrinologist's Point of View
EMPA-REG OUTCOME: The Endocrinologist's Point of View
Empagliflozin (Jardiance®)
CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?
CV Risk reduction in T2DM with GLP-1 Agonists: Should We Change Our Clinical Practice?
New Data on the Safety of SGLT2 Inhibitors
SGLT2 Inhibitors: What Do the Data Mean for My Patients?
Updates on CVOT Data and Clinical Comparisons That Matter
Global Projections for Diabetes:
Expert Panelists. Emerging CV Outcomes Trial Results: What Do They Mean for T2D Management?
CV Risk Management in T2DM: What Did We Learn From EASD 2016?
Select Topics in Cardiovascular Medicine
Updates on Outcomes for Novel T2D Therapies
SGLT2 Inhibitors in Phase 3 Trials
Novel Developments & Latest Clinical Results With Long-Acting GLP-1 Receptor Agonists.
SGLT2 Inhibitors and CV Outcomes
Looking Beyond Glucose Control: Multifactorial Management of Type 2 Diabetes.
Latest Cardiovascular Outcomes Trials: A Closer Look at the LEADER Results.
Impacting CV Risk With Diabetes Medications
EMPA-REG OUTCOME: The Endocrinologist's Point of View
EMPA-REG OUTCOME Trial design: Patients with type 2 diabetes mellitus (DM2) at high risk for CV events were randomized to receive in a 1:1:1 fashion either.
Impacting CV Risk With Diabetes Medications
Clinical Application of New CV Outcomes Data
T2DM and CV Outcomes Trials: A Deep Dive!
A Deep Dive Into CVOTs.
Expert Appraisal of CV Outcome Trial Results in T2DM for the Diabetologist.
Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?
Diabetes and CV Risk Reduction: Cardiologists’ Perspectives on the Latest Outcomes Data.
SGLT2 inhibitors, Now Part of the Cardiology Toolkit for Comprehensive CV Risk Management.
A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.
UKPDS 34: Metformin vs Conventional Glycemic Control on Outcomes
Case Study Role of DPP-4 Inhibitors
Tackling CV Risk in T2DM.
2008 FDA Guidance. Working as a Team for Cardiovascular Risk Reduction in Patients With T2D.
Breaking Down the CVOTs
CV Risk Management in T2DM: What Did We Learn from ADA 2016?
Heart Failure Hospitalization Risks with DPP-IV Inhibitors: Myth or Reality?
Type 2 Diabetes Management:  Where Are We Heading in Our Efforts to Control CV Risk?
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus
LEADER One Year On.
GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?
Novel Approaches to T1D Management
Antihyperglycemic Therapy
T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight
T2DM, CV Risk, and Modulating Risk With Glucose-Lowering Strategies
CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?
The Role of the Kidney in Glucose Control
Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.
Dual SGLT1/SGLT2 Inhibition in T1D
Updates From ACC.
Add-On Therapy to Insulin in T1DM Management
Patient Selection for Modern T2D Agents
Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?
2015 EASD In Review: CV Risk management in t2dm
TRUE-AHF Trial design: Patients with acute decompensated heart failure were randomized in a 1:1 fashion to either early ularitide infusion (within 12 hours)
Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.
Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?
New Approaches for Type 2 Diabetes -- GLP-1 RAs Now and in the Future
EMPA-REG OUTCOME: Cumulative incidence of the primary outcome
What's New in Oral Combination Therapy for Type 2 Diabetes?
Emerging Advances in Reducing Renal Complications of T2D
BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS
Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.
The Expanding Role of SGLT Inhibitors Across the Diabetes Spectrum
Presentation transcript:

ADA/EASD Position Statement: Approach to Hyperglycemia Management

ADA/EASD Position Statement: Antihyperglycemic Therapy in T2DM

SGLT2 Inhibitors: Weight Reduction in Randomized Trials as Add-On to Metformin

SGLT2 Inhibitors: Glycemic Control Comparison as Add-On to Metformin

EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on Individual CV Endpoints

EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on All-Cause Mortality and HF Hospitalization

AEs in Pooled, Placebo-Controlled Studies of Dapagliflozin

Abbreviations

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.